Algorae Pharmaceuticals Ltd

1AI

Company Profile

  • Business description

    Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer’s disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

  • Contact

    525 Collins Street
    Level 23, Rialto South Tower
    MelbourneVIC3000
    AUS

    T: +61 422180317

    https://www.algoraepharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    48

Stocks News & Analysis

stocks

Microsoft earnings: Strong, including Azure, but overall guidance is in line

We think Microsoft stock is moderately undervalued.
stocks

After earnings, is Tesla stock a buy, a sell, or fairly valued?

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
stocks

3 cheap fully franked stocks

Well priced Aussie shares that offer a tax rebate.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,178.0028.70-0.31%
CAC 408,121.7979.09-0.96%
DAX 4024,002.24116.65-0.48%
Dow JONES (US)47,522.12109.88-0.23%
FTSE 1009,727.6432.42-0.33%
HKSE25,906.65376.04-1.43%
NASDAQ23,581.14377.33-1.57%
Nikkei 22552,411.341,085.732.12%
NZX 50 Index13,548.3289.030.66%
S&P 5006,822.340.000.00%
S&P/ASX 2008,881.9031.30-0.35%
SSE Composite Index3,954.7932.11-0.81%

Market Movers